These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 21849294)

  • 1. Deep sequencing of plasma and proviral HIV-1 to establish coreceptor usage: what is the clinical impact of the quasispecies distribution?
    Abbate I; Rozera G; Giombini E; D'Offizi G; Nicastri E; Narciso P; Ippolito G; Capobianchi MR
    J Infect Dis; 2011 Sep; 204(6):971-3; author reply 973-4. PubMed ID: 21849294
    [No Abstract]   [Full Text] [Related]  

  • 2. Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients.
    Swenson LC; Mo T; Dong WW; Zhong X; Woods CK; Jensen MA; Thielen A; Chapman D; Lewis M; James I; Heera J; Valdez H; Harrigan PR
    J Infect Dis; 2011 Jan; 203(2):237-45. PubMed ID: 21288824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.
    Svicher V; Balestra E; Cento V; Sarmati L; Dori L; Vandenbroucke I; D'Arrigo R; Buonomini AR; Van Marck H; Surdo M; Saccomandi P; Mostmans W; Aerssens J; Aquaro S; Stuyver LJ; Andreoni M; Ceccherini-Silberstein F; Perno CF
    Antiviral Res; 2011 Apr; 90(1):42-53. PubMed ID: 21349294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Methods for determination of HIV tropism and their clinical use].
    Gutiérrez F; Rodríguez JC; García F; Poveda E
    Enferm Infecc Microbiol Clin; 2011 Dec; 29 Suppl 5():45-50. PubMed ID: 22305669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of co-receptor usage of circulating viral and proviral HIV genome quasispecies by ultra-deep pyrosequencing in patients who are candidates for CCR5 antagonist treatment.
    Abbate I; Rozera G; Tommasi C; Bruselles A; Bartolini B; Chillemi G; Nicastri E; Narciso P; Ippolito G; Capobianchi MR
    Clin Microbiol Infect; 2011 May; 17(5):725-31. PubMed ID: 20731681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reanalysis of coreceptor tropism in HIV-1-infected adults using a phenotypic assay with enhanced sensitivity.
    Wilkin TJ; Goetz MB; Leduc R; Skowron G; Su Z; Chan ES; Heera J; Chapman D; Spritzler J; Reeves JD; Gulick RM; Coakley E
    Clin Infect Dis; 2011 Apr; 52(7):925-8. PubMed ID: 21427401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High concordance of genotypic coreceptor prediction in plasma-viral RNA and proviral DNA of HIV-1 subtype C: implications for use of whole blood DNA in resource-limited settings.
    Gupta S; Neogi U; Srinivasa H; Shet A
    J Antimicrob Chemother; 2013 Sep; 68(9):2003-6. PubMed ID: 23633683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in HIV-1 tropism: clinical and prognostic consequences.
    Mosier DE
    Eur J Med Res; 2007 Oct; 12(9):371-4. PubMed ID: 17933716
    [No Abstract]   [Full Text] [Related]  

  • 9. Maraviroc, a CCR5 coreceptor antagonist that blocks entry of human immunodeficiency virus type 1.
    Hunt JS; Romanelli F
    Pharmacotherapy; 2009 Mar; 29(3):295-304. PubMed ID: 19249948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maraviroc treatment in non-R5-HIV-1-infected patients results in the selection of extreme CXCR4-using variants with limited effect on the total viral setpoint.
    McGovern RA; Symons J; Poon AF; Harrigan PR; van Lelyveld SF; Hoepelman AI; van Ham PM; Dong W; Wensing AM; Nijhuis M
    J Antimicrob Chemother; 2013 Sep; 68(9):2007-14. PubMed ID: 23677920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of cellular HIV DNA to predict virologic response to maraviroc: performance of population-based and deep sequencing.
    Swenson LC; Dong WW; Mo T; Demarest J; Chapman D; Ellery S; Heera J; Valdez H; Poon AF; Harrigan PR
    Clin Infect Dis; 2013 Jun; 56(11):1659-66. PubMed ID: 23429552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rescue of HIV-1 long-time archived X4 strains to escape maraviroc.
    Baatz F; Struck D; Lemaire M; De Landtsheer S; Servais JY; Arendt V; Schmit JC; Perez Bercoff D
    Antiviral Res; 2011 Dec; 92(3):488-92. PubMed ID: 22020304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of a commercial HIV co-receptor tropism assay in clinical practice.
    McCarthy MW; Genzen JR; Wilkin TJ; Singh HK
    AIDS Patient Care STDS; 2015 Feb; 29(2):53-4. PubMed ID: 25290122
    [No Abstract]   [Full Text] [Related]  

  • 14. The design and validation of a novel phenotypic assay to determine HIV-1 coreceptor usage of clinical isolates.
    Lin NH; Negusse DM; Beroukhim R; Giguel F; Lockman S; Essex M; Kuritzkes DR
    J Virol Methods; 2010 Oct; 169(1):39-46. PubMed ID: 20599562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents.
    MacArthur RD; Novak RM
    Clin Infect Dis; 2008 Jul; 47(2):236-41. PubMed ID: 18532888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High prevalence of X4/DM-tropic variants in children and adolescents infected with HIV-1 by vertical transmission.
    Briz V; García D; Méndez-Lagares G; Ruiz-Mateos E; de Mulder M; Moreno-Pérez D; Navarro ML; León-Leal JA; de José MI; Ramos JT; Mellado MJ; González-Tomé MI; Leal M; Muñoz-Fernández MA
    Pediatr Infect Dis J; 2012 Oct; 31(10):1048-52. PubMed ID: 22828644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of the HIV Tropism Test TROCAI Using the Virological Response to a Short-Term Maraviroc Monotherapy Exposure.
    Gonzalez-Serna A; Genebat M; De Luna-Romero M; Tarancon-Diez L; Dominguez-Molina B; Pacheco YM; Muñoz-Fernández MA; Leal M; Ruiz-Mateos E
    Antimicrob Agents Chemother; 2016 Oct; 60(10):6398-401. PubMed ID: 27480849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are the proposed env mutations actually associated with resistance to maraviroc?
    Saracino A; Monno L; Brindicci G; Trillo G; Altamura M; Punzi G; Lagioia A; Angarano G
    J Acquir Immune Defic Syndr; 2010 Apr; 53(4):550-2. PubMed ID: 20220379
    [No Abstract]   [Full Text] [Related]  

  • 19. HIV-1 coreceptor usage in paired plasma RNA and proviral DNA from patients with acute and chronic infection never treated with antiretroviral therapy.
    Bon I; Turriziani O; Musumeci G; Clò A; Montagna C; Morini S; Calza L; Gibellini D; Antonelli G; Re MC
    J Med Virol; 2015 Feb; 87(2):315-22. PubMed ID: 25138591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary resistance to maraviroc in a large set of R5-V3 viral sequences from HIV-1-infected patients.
    Seclén E; González Mdel M; Lapaz M; Rodríguez C; del Romero J; Aguilera A; de Mendoza C; Soriano V; Poveda E
    J Antimicrob Chemother; 2010 Dec; 65(12):2502-4. PubMed ID: 20940179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.